देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
SILDENAFIL (SILDENAFIL CITRATE)
APOTEX INC
G04BE03
SILDENAFIL
25MG
TABLET
SILDENAFIL (SILDENAFIL CITRATE) 25MG
ORAL
4
Prescription
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Active ingredient group (AIG) number: 0136261001; AHFS:
APPROVED
2012-11-09
_ _ _APO-SILDENAFIL (sildenafil citrate) _ _–_ _ Product Monograph _ _Page 1 of 57_ PRODUCT MONOGRAPH PR APO-SILDENAFIL Sildenafil Tablets Tablets, 25 mg, 50 mg and 100 mg sildenafil (as sildenafil citrate) Apotex Standard cGMP-Specific Phosphodiesterase Type 5 Inhibitor Treatment of Erectile Dysfunction Apotex Inc. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Revision: April 5, 2023 Submission Control No: 268822 _APO-SILDENAFIL (sildenafil citrate) _ _–_ _ Product Monograph _ _Page 2 of 57_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ...............................................................................3 INDICATIONS AND CLINICAL USE .....................................................................................3 CONTRAINDICATIONS ...........................................................................................................3 WARNINGS AND PRECAUTIONS .........................................................................................4 ADVERSE REACTIONS ...........................................................................................................7 DRUG INTERACTIONS .........................................................................................................12 DOSAGE AND ADMINISTRATION .....................................................................................16 OVERDOSAGE ........................................................................................................................17 ACTION AND CLINICAL PHARMACOLOGY ....................................................................18 STORAGE AND STABILITY .................................................................................................21 SPECIAL HANDLING INSTRUCTIONS ...............................................................................21 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................21 PART II: SCIENTIFIC IN पूरा दस्तावेज़ पढ़ें